Over the past year, the best-performing drugmaker stocks all have had one thing in common: They received very little attention before providing patient investors windfall gains. Being considered insignificant in itself isn’t a great reason to scoop up shares of Teligent Brian Feroldi : Being called a “specialty generic” drug manufacturer might sound oxymoronic, but Teligent has stumbled on a clever business strategy that could make it a great stock to put on your watch list.
Category: Portola Pharmaceuticals
Biotech Poised for Rebound
… election of Donald Trump has buoyed the prospects of financials, energy and industrials. After an initial surge, health-care and biotech have not benefited nearly as much as other industries but definitely not as badly as utilities or consumer …
Portola Pharmaceuticals Announces FDA Accepts New Drug Application…
Portola Pharmaceuticals, Inc.A today announced that the U.S. Food and Drug Administration accepted Portola’s New Drug Application granting priority review for betrixaban, an oral, once-daily Factor Xa inhibitor anticoagulant, for extended-duration prophylaxis of venous thromboembolism in acute medically ill patients with risk factors for VTE. A priority review shortens the FDA review timeline to six months from the standard review period of 10 months.